The Daily Buyout
UndisclosedMergerHealthcare & Life Sciences

Pulmatrix holders approve Eos SENOLYTIX merger

Pulmatrix has received stockholder approval and SEC effectiveness for its merger with Eos SENOLYTIX, a private biotech developing peptides for aging-related diseases. Closing still depends on Nasdaq listing approval and a reverse stock split, and is expected by year-end.

Read the full coverage, free

We only link to sources you can read without a subscription. How we check.

Following healthcare M&A?

The next big healthcare deal will be in our email the morning after it's announced, with the rest of the day's biggest deals. Free, with no paywalled links.

Free · Unsubscribe anytime

See what you get →